Illumina Reports Financial Results for Third Quarter of Fiscal Year 2012

SAN DIEGO--(BUSINESS WIRE)--Oct. 23, 2012-- Illumina, Inc. (NASDAQ:ILMN) today announced financial results for the third quarter of 2012.

Third quarter 2012 results:

• Revenue of $286 million, a 21% increase compared to $235 million in the third quarter of 2011.
• GAAP net income for the quarter of $30 million, or $0.22 per diluted share, compared to net income of $20 million, or $0.15 per diluted share, for the third quarter of 2011.
• Non-GAAP net income for the quarter of $54 million, or $0.41 per diluted share, compared to $30 million, or $0.22 per diluted share, for the third quarter of 2011 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures).
• Cash flow from operations of $51 million compared to cash flow from operations of $90 million for the third quarter of 2011 primarily due to changes in working capital associated with the timing of shipments.

Gross margin in the third quarter of 2012 was 68.5% compared to 66.7% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation and amortization of acquired intangibles, non-GAAP gross margin was 70.5% for the third quarter of 2012 compared to 68.9% in the prior year period.

Research and development (R&D) expenses for the third quarter of 2012 were $54.1 million compared to $50.4 million in the third quarter of 2011. R&D expenses included $7.8 million and $8.6 million of non-cash stock compensation expense in the third quarters of 2012 and 2011, respectively. Excluding these charges and contingent compensation, R&D expenses as a percentage of revenue were 15.9% compared to 17.4% in the prior year period.

Selling, general and administrative (SG&A) expenses for the third quarter of 2012 were $69.8 million compared to $66.0 million for the third quarter of 2011. SG&A expenses included $13.2 million and $13.8 million of non-cash stock compensation expense in the third quarters of 2012 and 2011, respectively. Excluding these charges, contingent compensation, and acquired intangible asset amortization, SG&A expenses as a percentage of revenue were 19.5% compared to 22.2% in the prior year period.

Depreciation and amortization expenses were $15.8 million and capital expenditures were $17.7 million during the third quarter of 2012. The company ended the quarter with $1.2 billion in cash, cash equivalents and short-term investments which is essentially unchanged from January 1, 2012.

Highlights since our last earnings release

• Completed the acquisition of BlueGnome, a leading provider of cytogenetics and in vitro fertilization (IVF) screening products
• Announced expedited Individual Genome Sequencing Services (IGS), powered by HiSeq® 2500 to enable breakthrough turnaround time, available via Illumina's CLIA-certified laboratory
• Announced an alliance with Partners HealthCare to introduce next-generation sequencing (NGS) clinical interpretation and reporting tools
• Announced TruSight™ targeted sequencing content sets, enabling labs to offer cost-effective, streamlined, targeted sequencing solutions for genetic diseases
• Held our inaugural 'Understand Your Genome' event
• Launched Infinium ® HumanCore Arrays for economical large-scale genetic studies
• Announced that the FDA selected the MiSeq® system for use in an extensive program to identify foodborne pathogens
• Launched TruSeq® Stranded mRNA and Total RNA Sequencing Sample Preparation solutions, delivering superior data quality for challenging samples and unprecedented views of the transcriptome
• Further strengthened Illumina's management team by appointing Paul Bianchi to Senior Vice President of Human Resources
• Announced a favorable outcome in patent litigation against Helicos BioSciences Corporation
• Repurchased $25 million of common stock under our previously announced share repurchase program

Financial outlook and guidance

“We are very pleased with our operational execution so far in 2012,” said Jay Flatley, Illumina's President and Chief Executive Officer. “As a result of our performance and the recent announcement regarding NIH funding under the continuing resolution, we are tightening our 2012 revenue and EPS guidance ranges. However, we remain cautious given the uncertainty of the U.S. fiscal cliff as well as the outcome of the Presidential election. Accordingly, we now expect 2012 revenue to be between $1.134 billion and $1.144 billion, (previous guidance was $1.1 billion to $1.175 billion), and non-GAAP earnings per fully diluted share to be between $1.54 and $1.59 (previous guidance was $1.50 to $1.60).”

Quarterly conference call information

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, October 23, 2012. Interested parties may listen to the call by dialing 888-679-8038 (passcode: 10421979), or, if outside North America, by dialing +1-617-213-4850 (passcode: 10421979). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 4:00 pm Pacific Time (7:00 pm Eastern Time) on October 23, 2012 through October 30, 2012 by dialing 888-286-8010 (passcode: 78765276), or if outside North America by dialing +1-617-801-6888 (passcode: 78765276).

Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating expenses, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

The company's financial measures under GAAP include substantial charges related to stock compensation expense, non-cash interest expense associated with the company's convertible debt instruments that may be settled in cash, headquarter relocation expense, costs related to unsolicited tender offer for the company's stock, amortization expense related to acquired intangible assets, contingent compensation expense, restructuring charges, legal contingencies, acquisition related expense, impairment of in-process research and development, and loss on extinguishment of debt. Per share amounts also include the double dilution associated with the accounting treatment of the company's 0.625% convertible senior notes outstanding and the corresponding call option overlay. Management believes that presentation of operating results that excludes these items and per share double dilution provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing the company's past and future operating performance.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.

Use of forward-looking statements

This release contains projections, information about our financial outlook, earnings guidance, and other forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to develop and commercialize further our sequencing, array, PCR, and consumables technologies and to deploy new products and applications, and expand the markets, for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; (iv) challenges inherent in developing, manufacturing, and launching new products and services; (v) our ability to maintain our revenue and profitability during periods of research funding reduction or uncertainty and adverse economic and business conditions, including as a result of slowing economic growth in the United States or worldwide, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current financial quarter.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its applications, paving the way for molecular medicine and ultimately transforming healthcare.

(a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.

(a) Pro forma impact of weighted average shares represents the impact of double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay.

(b) Headquarter relocation expense in Q3 2012 and first three quarters of 2012 consists primarily of cease-use loss recorded upon vacating our prior headquarters, double rent expense during the transition to our new headquarter facility, accretion of interest expense on lease exit liability recorded upon vacating certain buildings of our prior headquarters, and moving costs. Headquarter relocation expense recorded in Q3 2011 and first three quarters of 2011 consisted of accelerated depreciation expense and double rent expense during the transition to the new facility.

(c) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(d) Contingent compensation expense relates to contingent payments for post-combination services associated with acquisitions.

(e) Acquisition related (gain) expense, net during the first three quarters of 2012 year includes changes in fair value of contingent consideration of $1.7 million, $1.1 million, and $(1.1) million recorded in Q1, Q2, and Q3, respectively, and transaction costs related to acquisition of BlueGnome Ltd. of $0.7 million recorded in Q3. Acquisition related (gain) expense, net in Q3 2011 consists of change in fair value of contingent consideration of $2.6 million. Acquisition related (gain) expense, net in the first three quarters of 2011 consists of an acquired in-process research and development charge of $5.4 million in Q2 2011 related to a milestone payment for a prior acquisition, offset by changes in fair value of contingent consideration of $3.0 million.

(f) Incremental non-GAAP tax expense reflects the increase to GAAP tax expense related to the non-GAAP adjustments listed above.

(g) Non-GAAP net income per share and net income exclude the effect of the pro forma adjustments as detailed above. Non-GAAP diluted net income per share and net income are key drivers of our core operating performance and major factors in management's bonus compensation each year. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.

(a) Contingent compensation expense relates to contingent payments for post-combination services associated with acquisitions.

(b) Headquarter relocation expense in Q3 2012 and first three quarters of 2012 consists primarily of cease-use loss recorded upon vacating our prior headquarters, double rent expense during the transition to our new headquarter facility, accretion of interest expense on lease exit liability recorded upon vacating certain buildings of our prior headquarters, and moving costs. Headquarter relocation expense recorded in Q3 2011 and first three quarters of 2011 consisted of accelerated depreciation expense and double rent expense during the transition to the new facility.

(c) Acquisition related (gain) expense, net during the first three quarters of 2012 year includes changes in fair value of contingent consideration of $1.7 million, $1.1 million, and $(1.1) million recorded in Q1, Q2, and Q3, respectively, and transaction costs related to acquisition of BlueGnome Ltd. of $0.7 million recorded in Q3. Acquisition related (gain) expense, net in Q3 2011 consists of change in fair value of contingent consideration of $2.6 million. Acquisition related (gain) expense, net in the first three quarters of 2011 consists of an acquired in-process research and development charge of $5.4 million in Q2 2011 related to a milestone payment for a prior acquisition, offset by changes in fair value of contingent consideration of $3.0 million.

(d) Non-GAAP operating profit, and non-GAAP other income, net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. Non-GAAP gross profit, included within the non-GAAP operating profit, is a key measure of the effectiveness and efficiency of our manufacturing processes, product mix and the average selling prices of our products and services.

(e) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(b) We expect to incur additional headquarter relocation expenses, the majority of which are non-cash in nature. These expenses include items such as additional cease-use loss upon vacating our former headquarter facilities, accretion of interest expense on such cease-use liabilities, and double rent expense during the transition to the new facility.

(c) Contingent compensation expense represents contingent consideration for post-combination services associated with acquisitions.

(d) Acquisition related expense primarily represents changes in fair value of contingent consideration.

(e) Pro forma impact of weighted average shares represents the estimated impact of double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com